These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 28335463)
1. Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder? Magdalon J; Sánchez-Sánchez SM; Griesi-Oliveira K; Sertié AL Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335463 [TBL] [Abstract][Full Text] [Related]
2. Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC). Niere F; Namjoshi S; Song E; Dilly GA; Schoenhard G; Zemelman BV; Mechref Y; Raab-Graham KF Mol Cell Proteomics; 2016 Feb; 15(2):426-44. PubMed ID: 26419955 [TBL] [Abstract][Full Text] [Related]
3. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis. Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171 [TBL] [Abstract][Full Text] [Related]
4. Altered mTORC1 signaling in multipotent stem cells from nearly 25% of patients with nonsyndromic autism spectrum disorders. Suzuki AM; Griesi-Oliveira K; de Oliveira Freitas Machado C; Vadasz E; Zachi EC; Passos-Bueno MR; Sertie AL Mol Psychiatry; 2015 May; 20(5):551-2. PubMed ID: 25582616 [No Abstract] [Full Text] [Related]
5. mTOR, a Potential Target to Treat Autism Spectrum Disorder. Sato A CNS Neurol Disord Drug Targets; 2016; 15(5):533-43. PubMed ID: 27071790 [TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
7. Retrograde changes in presynaptic function driven by dendritic mTORC1. Henry FE; McCartney AJ; Neely R; Perez AS; Carruthers CJ; Stuenkel EL; Inoki K; Sutton MA J Neurosci; 2012 Nov; 32(48):17128-42. PubMed ID: 23197706 [TBL] [Abstract][Full Text] [Related]
10. Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. Schriever SC; Deutsch MJ; Adamski J; Roscher AA; Ensenauer R J Nutr Biochem; 2013 May; 24(5):824-31. PubMed ID: 22898570 [TBL] [Abstract][Full Text] [Related]
11. Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism. Machado CO; Griesi-Oliveira K; Rosenberg C; Kok F; Martins S; Passos-Bueno MR; Sertie AL Eur J Hum Genet; 2016 Jan; 24(1):59-65. PubMed ID: 25898924 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic target of rapamycin is necessary for changes in dendritic spine morphology associated with long-term potentiation. Henry FE; Hockeimer W; Chen A; Mysore SP; Sutton MA Mol Brain; 2017 Oct; 10(1):50. PubMed ID: 29084578 [TBL] [Abstract][Full Text] [Related]
13. Abnormal mTOR Activity in Pediatric Autoimmune Neuropsychiatric and MIA-Associated Autism Spectrum Disorders. Trifonova EA; Mustafin ZS; Lashin SA; Kochetov AV Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055151 [TBL] [Abstract][Full Text] [Related]
14. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Bidinosti M; Botta P; Krüttner S; Proenca CC; Stoehr N; Bernhard M; Fruh I; Mueller M; Bonenfant D; Voshol H; Carbone W; Neal SJ; McTighe SM; Roma G; Dolmetsch RE; Porter JA; Caroni P; Bouwmeester T; Lüthi A; Galimberti I Science; 2016 Mar; 351(6278):1199-203. PubMed ID: 26847545 [TBL] [Abstract][Full Text] [Related]
15. mTOR plays an important role in cow's milk allergy-associated behavioral and immunological deficits. Wu J; de Theije CG; da Silva SL; van der Horst H; Reinders MT; Broersen LM; Willemsen LE; Kas MJ; Garssen J; Kraneveld AD Neuropharmacology; 2015 Oct; 97():220-32. PubMed ID: 26027949 [TBL] [Abstract][Full Text] [Related]
16. Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD. Ben-Reuven L; Reiner O Dev Growth Differ; 2016 Jun; 58(5):481-91. PubMed ID: 27111774 [TBL] [Abstract][Full Text] [Related]
17. Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment. Vasic V; Jones MSO; Haslinger D; Knaus LS; Schmeisser MJ; Novarino G; Chiocchetti AG Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828352 [TBL] [Abstract][Full Text] [Related]